余发星

人才队伍

全聘课题组长

首页人才队伍全聘课题组长

余发星
博士，复旦大学生物医学研究院PI暨附属儿科医院双聘教授
地址：东安路131号，上海 200032
网站：http://yu-lab.fudan.edu.cn
邮箱：fxyu@fudan.edu.cn

工作经历

研究员，复旦大学，生物医学研究院（2014.9-今）
博士后，加州大学圣地亚哥分校，Moores肿瘤中心暨药理系（2010.7-2014.9）
研究助理，新加坡分子与细胞生物研究院（2004.8-2010.2）

教育经历

博士，新加坡国立大学，生物化学系，2010
学士，新加坡国立大学，生物化学系，2004

所获人才项目

杰出青年基金，国家自然科学基金委，2024
优秀青年基金，国家自然科学基金委，2016
上海高校特聘教授，上海市教委，2014

研究方向

实验室的主要研究方向为：（1）Hippo信号通路调控机制；（2）器官大小调控机制；（3）肿瘤基因、抗体治疗；（4）细胞群体迁移及肿瘤转移。研究团队主要利用小鼠等动物模型，结合生物化学、细胞生物学、遗传学、生物信息学以及临床样本分析等实验手段，解析Hippo通路的分子调节机制及其在组织损伤再生及肿瘤（消化道及儿童实体肿瘤）发生中的功能，同时也致力于研发靶向Hippo通路的药物。目前主持和参与多项国家或省部级项目，包括国家自然科学基金面上项目、优青项目，杰青项目，科技部重点研发项目及上海市科委项目。迄今，已在国内外学术刊物上发表论文60余篇，论文被引用1万余次（连续入选中国高被引学者）。其中，以通讯作者形式在Molecular Cell、Developmental Cell、The EMBO Journal、Science Advances、Cell Reports Medicine、Cell Research、Cell Reports、Oncogene、EMBO Reports、Protein & Cell等期刊发表研究论文，并在Cell、Science Bulletin、Protein & Cel、BioEssays、Cell Reports等期刊发表综述及观点文章。

招生专业

生物化学与分子生物学

代表论文

1.Wang Y, Wang Y, Zhu Y, Yu P, Zhou F, Zhang A, Gu Y, Jin R, Li J, Zheng F, Yu A, Ye D, Xu Y, Liu YJ, Saw TB, Hu G, Lin CT, Yu FX*. Angiomotin cleavage promotes leader formation and collective cell migration. Developmental Cell. 2025 Jan 6;60(1):101-118.e7.

2.Wang X, Zhu R, Yu P, Qi S, Zhong Z, Jin R, Wang Y, Gu Y, Ye D, Chen K, Shu Y, Wang Y, Yu FX*. WWC proteins-mediated compensatory mechanism restricts schwannomatosis driven by NF2 loss of function. Science Advances. 2025 Jan 24;11(4):eadp4765.

3.Zhu R, Liu X, Zhang X, Zhong Z, Qi S, Jin R, Gu Y, Wang Y, Ling C, Chen K, Ye D, Yu FX*. Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo. Cell Reports Medicine. 2024 Oct 15;5(10):101763.

4.Zhong Z, Jiao Z, Yu FX*. The Hippo signaling pathway in development and regeneration. Cell Reports. 2024 Mar 26;43(3):113926. (Selected as Best of Cell Reports 2024)

5.Wang Y, Zhu Y, Wang Y, Chang Y, Geng F, Ma M, Gu Y, Yu A, Zhu R, Yu P, Sha Z, Qi S, Li J, Zhao W, Pan W, Zhang R*, Yu FX*. Proteolytic activation of angiomotin by DDI2 promotes angiogenesis. TheEMBO Journal 2023 Jun 23:e112900.

6.Qi S, Zhong Z, Zhu Y, Wang Y, Ma M, Wang Y, Liu X, Jin R, Jiao Z, Zhu R, Sha Z, Dang K, Liu Y, Lim DS, Mao J, Zhang L, Yu FX*. Two Hippo signaling modules orchestrate liver size and tumorigenesis.TheEMBO Journal 2023 Jun 1;42(11):e112126. (Featured in News & Views)

7.Yu P, Qu N, Zhu R, Hu J, Han P, Wu J, Tan L, Gan H, He C, Fang C, Lei Y, Li J, He C, Lan F, Shi X, Wei W, Wang Y, Ji Q, Yu FX*, Wang YL*.TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Science Advances 2023 Sep;9(35):eadg7125.

8.Yu A, Yu P, Zhu Y, Zhu R, Sun R, Ye D, Yu FX*.Glucose-induced and ChREBP: MLX-mediated lipogenic program promotes hepatocellular carcinoma development. Oncogene 2023 Sep 9;

9.Zhong Z, Meng Z, Yu FX*.Reconstructing the Hippo signaling network. Science Bulletin 2023 Aug 28; S2095-9273(23)00588-1 (Perspective).

10.Ma M, Zhong Z, Zhu Y, Gu Y, Jin R, Meng Z, Wang Y*, Yu FX*. Phosphorylation of NF2 at Serine-13 by MAP4K family kinases mediates pathological angiogenesis. Protein Cell 2023 Mar 16;14(2):137-142.

11.Gu Y, Wang Y, Sha Z, He C, Zhu Y, Li J, Yu A, Zhong Z, Wang X, Sun Y, Lan F, Yu FX*.Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers. Cell Reports 2022 Aug 30;40(9):111296.

12.Qi S, Zhu Y, Liu X, Li P, Wang Y, Zeng Y, Yu A, Wang Y, Sha Z, Zhong Z, Zhu R, Yuan H, Ye D, Huang S, Ling C, Xu Y, Zhou D, Zhang L, Yu, FX*. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Molecular Cell 2022 May 19;82(10):1850-1864.

13.Wang, Y., Zhu, Y., Gu, Y., Ma, M., Wang, Y., Qi, S., Zeng, Y., Zhu, R., Wang, X., Yu, P., Xu, J., Shu, Y., and Yu, FX*. Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis. Cell Reports Dec 7;14(712):eabj8393.

14.Li Y, Li J, Wang R, Zhang L, Fu G, Wang X, Wang Y, Fang C, Zhang D, Du D, Ma X, Pan M, Guo Q, Xu X, Hu X, Zhou Y, Mo S, Wang H, Gao J, Huang S, Liu Y, Cai S, Hua G*, Peng J*, Yu FX*. Frequent RNF43 mutation contributes to moderate activation of Wnt signaling in colorectal signet-ring cell carcinoma. Protein & Cell 2020 Apr;11(4):292-298.

15.Pan, B., Yang, Y., Li, J., Wang, Y., Fang, C., Yu, FX.*, & Xu, Y. *(2020). USP47-mediated deubiquitination and stabilization of YAP contributes to the progression of colorectal cancer. Protein & Cell 11(2), 138-143.

16.Fang C, Li J, Qi S, Lei Y, Zeng Y, Yu P, Hu Z, Zhou Y, Wang Y, Dai R, Li J, Huang S, Xu P, Chen K, Ding C, Yu FX*. An alternatively transcribed TAZ variant negatively regulates JAK-STAT signaling. EMBO Reports 2019 Jun;20(6). pii: e47227.

17.Gong R, Hong AW, Plouffe SW, Zhao B, Liu G, Yu FX*,Xu Y*, Guan KL*. Opposing roles of conventional and nove PKC in the Hippo-YAP pathway regulation. Cell Research 2015 Aug;25(8):985-8.

18.Yu FX*, Zhao B, Guan KL*. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 2015 Nov 5;163(4):811-28 (Leading Edge Review).

19.Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, Zhao J, Chen X, Zhang L, Wang CY, Bastian BC, Zhang K, Guan KL. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014 Jun 16;25(6):822-30.

20.Yu FX, Zhang Y, Park HW, Jewell JL, Chen Q, Deng Y, Pan D, Taylor SS, Lai ZC, Guan KL. Protein Kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes & Development 2013 Jun 1;27(11):1223-32.

21.Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, Fu XD, Mill GB, Guan KL. Regulation of the Hippo-YAP pathway by G-protein coupled receptor signaling. Cell 2012 Aug 17;150(4):780-91.